Quantcast
Last updated on April 23, 2014 at 11:05 EDT

Latest Boehringer Ingelheim Corporation Stories

2013-04-23 12:32:03

- STARTVerso(TM)1 data presented in treatment-naive patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin RIDGEFIELD, Conn., April 23, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 STARTVerso(TM)1 trial of faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin (PegIFN/RBV). In previously untreated patients with genotype-1...

2013-04-08 08:30:51

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso(TM) 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress(TM) 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands. The STARTVerso(TM) 1 trial evaluated faldaprevir (BI 201335), an investigational...

2013-03-18 20:22:28

RIDGEFIELD, Conn., March 18, 2013 /PRNewswire/ -- A new perspective from the U.S. Food and Drug Administration (FDA) states the agency has not changed its recommendations regarding Pradaxa(®) (dabigatran etexilate mesylate) capsules, following the November 2012 Mini-Sentinel evaluations. The FDA stated that bleeding rates associated with new use of PRADAXA do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY(®)...

2013-03-05 08:29:16

RIDGEFIELD, Conn., March 5, 2013 /PRNewswire/ -- Boehringer Ingelheim will present data on dabigatran from four abstracts at the 62(nd) Annual Scientific Session of the American College of Cardiology (ACC) in San Francisco, Calif., from March 9 to 11, 2013. Detailed information regarding the data presentations include: Saturday, March 9, Poster Sessions Effect of Dabigatran on Serum Apo-Lipoprotein B and Apo-Lipoprotein A1 Concentrations (Lead Author: P. Joseph) [Abstract No....

2013-03-04 12:28:21

Interim Phase 3 STARTVerso(TM) 4 analysis in co-infected patients showed 80% protocol-defined early treatment success* RIDGEFIELD, Conn., March 4, 2013 /PRNewswire/ -- Today Boehringer Ingelheim Pharmaceuticals, Inc. announced the first interim results in HCV/HIV co-infected patients from the company's ongoing hepatitis C (HCV) clinical trial program, HCVerso(TM). These results, from the Phase 3 trial STARTVerso(TM) 4, were presented today at the 20(th) annual Conference on...

2013-02-23 12:20:18

Data presented at the 2013 American Academy of Allergy, Asthma & Immunology Annual Meeting SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma(TM) program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. In prespecified subgroups from two paired clinical trials, tiotropium delivered once daily via the Respimat® inhaler improved lung...

2013-02-20 16:25:02

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDY(SM) and RE-SONATE(®), show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine. VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and...

2013-01-29 16:24:46

RIDGEFIELD, Conn., Jan. 29, 2013 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in a new drug application (NDA) provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic...

2013-01-17 08:26:00

RIDGEFIELD, Conn., Jan. 17, 2013 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc. announced that the first patients have been enrolled in the company's pivotal Phase 3 interferon (IFN)-free hepatitis C (HCV) clinical trial program, HCVerso(TM). Boehringer Ingelheim's investigational IFN-free regimen combines the compounds faldaprevir (BI 201335), a protease inhibitor administered once-daily, and BI 207127, a non-nucleoside polymerase inhibitor administered twice-daily, plus...

2013-01-15 07:18:08

RIDGEFIELD, Conn., Jan. 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for afatinib is currently under review for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor...